Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$133.09

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $121.17 2
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Myriad Genetic Laboratories, Inc. $106.53 1
Novo Nordisk Inc $14.64 1
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1699985002?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $133.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $14.6412/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811377771 CMS
Myriad Genetic Laboratories, Inc. $106.5312/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834546673 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845870475 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

121 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $44,210.25 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754709
Principal investigator 1 Merck Sharp & Dohme Corporation $58,928.43 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754711
Principal investigator 1 Merck Sharp & Dohme Corporation $44,210.25 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO NORTHEAST
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754837
Principal investigator 1 Merck Sharp & Dohme Corporation $44,210.25 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO STONE OAK
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754839
Principal investigator 1 Merck Sharp & Dohme Corporation $44,210.25 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY NEW BRAUNFELS
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754841
Principal investigator 1 Merck Sharp & Dohme Corporation $78,676.05 12/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY NEW BRAUNFELS
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754877
Principal investigator 1 Seagen Inc. $30.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659599
Principal investigator 1 Seagen Inc. $3,430.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659605
Principal investigator 1 Seagen Inc. $30.00 12/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659677
Principal investigator 1 Seagen Inc. $4,123.96 12/14/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659717
Principal investigator 1 Seagen Inc. $4,123.96 12/14/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659719
Principal investigator 1 SANOFI US SERVICES INC. $1,125.00 12/06/2021 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 838653255
Principal investigator 1 Seagen Inc. $4,123.96 11/22/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659715
Principal investigator 1 Seagen Inc. $4,123.96 11/22/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659733
Principal investigator 1 Merck Sharp & Dohme Corporation $6,925.00 11/17/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 848754707
Principal investigator 1 Seagen Inc. $295.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659587
Principal investigator 1 Seagen Inc. $2,150.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659589
Principal investigator 1 Seagen Inc. $30.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659593
Principal investigator 1 Seagen Inc. $295.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659669
Principal investigator 1 Seagen Inc. $2,150.00 11/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659671
Principal investigator 1 Seagen Inc. $4,123.96 11/04/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659713
Principal investigator 1 Seagen Inc. $4,123.96 11/04/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659731
Principal investigator 1 Eli Lilly and Company $10,200.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 819467411
Principal investigator 1 Genentech, Inc. $2,550.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 836026681
Principal investigator 1 Seagen Inc. $450.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659577
Principal investigator 1 Seagen Inc. $2,150.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659581
Principal investigator 1 Seagen Inc. $30.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659585
Principal investigator 1 Seagen Inc. $956.00 10/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659645
Principal investigator 1 Seagen Inc. $4,123.96 10/11/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659711
Principal investigator 1 Seagen Inc. $4,123.96 10/11/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659729
Principal investigator 1 Novartis Pharmaceuticals Corporation $90.00 10/01/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY
EPIK-B2: A TWO PART, PHASE III, MULTICENTER, RANDOMIZED (1:1), DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER WITH A PIK3CA MUTATION No dispute reported 06/30/2026 800646235
Principal investigator 1 Seagen Inc. $4,123.96 09/21/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659709
Principal investigator 1 Seagen Inc. $4,123.96 09/21/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659727
Principal investigator 1 Seagen Inc. $3,430.00 09/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659637
Principal investigator 1 Eli Lilly and Company $38.20 09/08/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 819470149
Principal investigator 1 Seagen Inc. $4,123.96 08/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659707
Principal investigator 1 Seagen Inc. $4,123.96 08/31/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659725
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,650.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 826498231
Principal investigator 1 Seagen Inc. $2,150.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659625
Principal investigator 1 Seagen Inc. $30.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659627
Principal investigator 1 Seagen Inc. $2,150.00 08/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659701
Principal investigator 1 Seagen Inc. $4,123.96 08/10/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659705
Principal investigator 1 Seagen Inc. $4,123.96 08/10/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659723
Principal investigator 1 Eli Lilly and Company $32.00 07/27/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 819469793
Principal investigator 1 PFIZER INC. $6,250.00 07/21/2021 Non-covered Recipient Entity
US Oncology Research LLC
A PHASE 2 NON RANDOMIZED OPEN LABEL SINGLE ARM MULTI CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA12 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER No dispute reported 06/30/2026 832611329
Principal investigator 1 Seagen Inc. $4,123.96 07/19/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659703
Principal investigator 1 Seagen Inc. $4,123.96 07/19/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659721
Principal investigator 1 Seagen Inc. $2,150.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659607
Principal investigator 1 Seagen Inc. $956.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659611
Principal investigator 1 Seagen Inc. $30.00 07/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659613
Principal investigator 1 Seagen Inc. $4,123.96 06/30/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659529
Principal investigator 1 Seagen Inc. $4,123.96 06/30/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659565
Principal investigator 1 Seagen Inc. $3,230.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659431
Principal investigator 1 Seagen Inc. $1,950.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659435
Principal investigator 1 Seagen Inc. $30.00 06/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659437
Principal investigator 1 Seagen Inc. $4,123.96 06/08/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659527
Principal investigator 1 Seagen Inc. $4,123.96 06/08/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659563
Principal investigator 1 Seagen Inc. $4,123.96 05/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659525
Principal investigator 1 Seagen Inc. $4,123.96 05/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659561
Principal investigator 1 Seagen Inc. $2,145.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659423
Principal investigator 1 Seagen Inc. $1,841.00 05/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659425
Principal investigator 1 Seagen Inc. $4,123.96 04/28/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659523
Principal investigator 1 Seagen Inc. $4,123.96 04/28/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659559
Principal investigator 1 Genentech, Inc. $1,275.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 836026603
Principal investigator 1 Seagen Inc. $3,636.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659403
Principal investigator 1 Seagen Inc. $2,140.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659411
Principal investigator 1 Seagen Inc. $450.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659413
Principal investigator 1 Seagen Inc. $956.00 04/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659471
Principal investigator 1 Seagen Inc. $4,123.96 04/06/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659521
Principal investigator 1 Seagen Inc. $4,123.96 04/06/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659557
Principal investigator 1 SANOFI US SERVICES INC. $8,000.00 03/29/2021 Non-covered Recipient Entity
US Oncology Research LLC Attn Accounts Receivable
A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease No dispute reported 06/30/2026 838653071
Principal investigator 1 Seagen Inc. $4,123.96 03/17/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659509
Principal investigator 1 Seagen Inc. $4,123.96 03/17/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659541
Principal investigator 1 Seagen Inc. $4,123.96 03/16/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659507
Principal investigator 1 Seagen Inc. $4,123.96 03/16/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659539
Principal investigator 1 Seagen Inc. $2,610.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659355
Principal investigator 1 Seagen Inc. $3,430.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659357
Principal investigator 1 Seagen Inc. $450.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659359
Principal investigator 1 Seagen Inc. $30.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659451
Principal investigator 1 Seagen Inc. $30.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659453
Principal investigator 1 Seagen Inc. $30.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659457
Principal investigator 1 Seagen Inc. $30.00 03/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659459
Principal investigator 1 Seagen Inc. $4,123.96 02/25/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659505
Principal investigator 1 Seagen Inc. $4,123.96 02/25/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659537
Principal investigator 1 Seagen Inc. $4,123.96 02/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659503
Principal investigator 1 Seagen Inc. $4,123.96 02/23/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659535
Principal investigator 1 Seagen Inc. $2,851.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659391
Principal investigator 1 Seagen Inc. $2,150.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659393
Principal investigator 1 Seagen Inc. $2,150.00 02/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659455
Principal investigator 1 Seagen Inc. $4,123.96 02/03/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659501
Principal investigator 1 Seagen Inc. $4,123.96 02/03/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659533
Principal investigator 1 Seagen Inc. $4,123.96 02/01/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659499
Principal investigator 1 Seagen Inc. $4,123.96 02/01/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659531
Principal investigator 1 Seagen Inc. $4,123.96 01/25/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659519
Principal investigator 1 Seagen Inc. $4,123.96 01/25/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659555
Principal investigator 1 Seagen Inc. $4,123.96 01/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659517
Principal investigator 1 Seagen Inc. $4,123.96 01/18/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659553
Principal investigator 1 Eli Lilly and Company $34,294.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819467301
Principal investigator 1 Genentech, Inc. $1,275.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
PHASE III IN CDK4 6 INHIBITOR EXPERIENCED PIK3CA MUTANT HR HER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 836026759
Principal investigator 1 Seagen Inc. $30.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659365
Principal investigator 1 Seagen Inc. $3,430.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659367
Principal investigator 1 Seagen Inc. $85.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659371
Principal investigator 1 Seagen Inc. $1,445.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659373
Principal investigator 1 Seagen Inc. $2,000.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659375
Principal investigator 1 Seagen Inc. $500.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659377
Principal investigator 1 Seagen Inc. $2,150.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659379
Principal investigator 1 Seagen Inc. $2,865.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659381
Principal investigator 1 Seagen Inc. $956.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659383
Principal investigator 1 Seagen Inc. $40.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659385
Principal investigator 1 Seagen Inc. $188.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659387
Principal investigator 1 Seagen Inc. $4,263.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659389
Principal investigator 1 Seagen Inc. $1,445.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659467
Principal investigator 1 Seagen Inc. $1,445.00 01/15/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659469
Principal investigator 1 Eli Lilly and Company $80,345.00 01/12/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819468769
Principal investigator 1 Seagen Inc. $4,123.96 01/12/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659515
Principal investigator 1 Seagen Inc. $4,123.96 01/12/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659551
Principal investigator 1 Seagen Inc. $4,123.96 01/07/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659513
Principal investigator 1 Seagen Inc. $4,123.96 01/07/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659549
Principal investigator 1 Eli Lilly and Company $0.18 01/06/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819469633
Principal investigator 1 Seagen Inc. $4,123.96 01/04/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659511
Principal investigator 1 Seagen Inc. $4,123.96 01/04/2021 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 792659547